Sanofi-Aventis Sues Over Eloxatin Ingredient

Law360, New York (May 2, 2008, 12:00 AM EDT) -- Sanofi-Aventis has filed suit against W.C. Heraeus GmbH, claiming the German precious metals company is aiding infringement of a patent for Sanofi’s colon cancer drug Eloxatin by providing an important active pharmaceutical ingredient to three generics makers.

The suit against Heraeus is the 15th that Sanofi has filed in the U.S. District Court for the District of New Jersey in an effort to prevent pharmaceutical companies from marketing generic versions of oxaliplatin, the active ingredient in Eloxatin.

In its most recent complaint, the French pharmaceutical company,...
To view the full article, register now.